DOCSLIB.ORG

The Purple Book

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
The Purple Book ADVANCING CLINICALLY APPROPRIATE LAB TECHNOLOGY AND SERVICES The Prior Authorization List For BlueCross BlueShield of South Carolina and BlueChoice HealthPlan (Sept. 1, 2020) Visit us at Avalonhcs.com BlueCross ® BlueShield® of South Carolina is an independent licensee of the Blue Cross and Blue Shield Association. About Prior Authorization BlueCross Blue Shield of South Carolina and BlueChoice HealthPlan have delegated prior authorization (PA) for outpatient lab services to Avalon Healthcare Solutions (Avalon). Avalon is an independent company that performs outpatient lab services on behalf of BlueCross and BlueChoice®. Avalon does not review requests for services provided in an emergency room, surgery center or hospital inpatient place of service. Avalon, BlueCross and BlueChoice have determined that certain lab services require prior authorization and require that you request that Avalon review these services prior to performing the services. You may submit requests for prior authorization to Avalon by fax (888-791-2181), by phone (844-227-5769), or online using Avalon’s Prior Authorization System, 8 a.m. – 8 p.m., Eastern Time. Once Avalon receives your request, it will be reviewed by Avalon’s clinical staff and they will notify you of their determination. An authorization does not guarantee payment. As always, payment is subject to the member’s plan coverage and benefits at the time the service is performed. 2020 Code Revision Legend Yellow – Existing codes that will no longer require PA, not intended to imply coverage Green – Codes added to the PA list Codes Requiring Prior Authorization Procedure PA for PA for Description Code 7/1/2020 9/1/2020 IDH1 (isocitrate dehydrogenase 1 [NADP+], soluble) (e.g., glioma), common 81120 Yes Yes variants (e.g., R132H, R132C) IDH2 (isocitrate dehydrogenase 2 [NADP+], mitochondrial) (e.g., glioma), 81121 Yes Yes common variants (e.g., R140W, R172M) DMD (dystrophin) (e.g., Duchenne/Becker muscular dystrophy) deletion 81161 Yes Yes analysis, and duplication analysis, if performed BRCA1 (BRCA1, DNA repair associated), BRCA2 (BRCA2, DNA repair associated) (e.g., hereditary breast and ovarian cancer) gene analysis; full 81162 Yes Yes sequence analysis and full duplication/deletion analysis (i.e., detection of large gene rearrangements) BRCA1 (BRCA1, DNA repair associated), BRCA2 (BRCA2, DNA repair 81163 associated) (e.g., hereditary breast and ovarian cancer) gene analysis Yes Yes (breast cancer 1 and 2) of full sequence BRCA1 (BRCA1, DNA repair associated), BRCA2 (BRCA2, DNA repair 81164 associated) (e.g., hereditary breast and ovarian cancer) gene analysis; full Yes Yes duplication/deletion analysis (i.e., detection of large gene rearrangements) BRCA1 (BRCA1, DNA repair associated) (e.g., hereditary breast and ovarian 81165 Yes Yes cancer) gene analysis; full sequence analysis BRCA1 (BRCA1, DNA repair associated) (e.g., hereditary breast and ovarian 81166 cancer) gene analysis; full duplication/deletion analysis (i.e., detection of Yes Yes large gene rearrangements) Confidential and Proprietary Information of Avalon Health Services, LLC, d/b/a Avalon Healthcare Solutions PA-TOOL-6032-V02-20170124-Prior Authorization List 1 Procedure PA for PA for Description Code 7/1/2020 9/1/2020 BRCA2 (BRCA2, DNA repair associated) (e.g., hereditary breast and ovarian 81167 cancer) gene analysis; full duplication/deletion analysis (i.e., detection of Yes Yes large gene rearrangements) ABL1 (ABL proto-oncogene 1, non-receptor tyrosine kinase) (e.g., acquired 81170 imatinib tyrosine kinase inhibitor resistance), gene analysis, variants in the Yes Yes kinase domain AFF2 (AF4/FMR2 family, member 2 [FMR2]) (e.g., fragile X mental 81171 retardation 2 [FRAXE]) gene analysis; evaluation to detect abnormal (e.g., Yes Yes expanded) alleles AFF2 (AF4/FMR2 family, member 2 [FMR2]) (e.g., fragile X mental 81172 retardation 2 [FRAXE]) gene analysis; characterization of alleles (e.g., Yes Yes expanded size and methylation status) AR (androgen receptor) (e.g., spinal and bulbar muscular atrophy, Kennedy 81173 Yes Yes disease, X chromosome inactivation) gene analysis; full gene sequence ASXL1 (additional sex combs like 1, transcriptional regulator) (e.g., 81175 myelodysplastic syndrome, myeloproliferative neoplasms, chronic Yes Yes myelomonocytic leukemia) gene analysis; full gene sequence ASXL1 (additional sex combs like 1, transcriptional regulator) (e.g., myelodysplastic syndrome, myeloproliferative neoplasms, chronic 81176 Yes Yes myelomonocytic leukemia) gene analysis; targeted sequence analysis (e.g., exon 12) ATN1 (atrophin 1) (e.g., dentatorubral-pallidoluysian atrophy) gene 81177 Yes Yes analysis, evaluation to detect abnormal (e.g., expanded) alleles ATXN1 (ataxin 1) (e.g., spinocerebellar ataxia) gene analysis, evaluation to 81178 Yes Yes detect abnormal (e.g., expanded) alleles ATXN2 (ataxin 2) (e.g., spinocerebellar ataxia) gene analysis, evaluation to 81179 Yes Yes detect abnormal (e.g., expanded) allele ATXN3 (ataxin 3) (e.g., spinocerebellar ataxia, Machado-Joseph disease) 81180 Yes Yes gene analysis, evaluation to detect abnormal (e.g., expanded) alleles ATXN7 (ataxin 7) (e.g., spinocerebellar ataxia) gene analysis, evaluation to 81181 Yes Yes detect abnormal (e.g., expanded) alleles ATXN8OS (ATXN8 opposite strand [non-protein coding]) (e.g., 81182 spinocerebellar ataxia) gene analysis, evaluation to detect abnormal (e.g., Yes Yes expanded) alleles ATXN10 (ataxin 10) (e.g., spinocerebellar ataxia) gene analysis, evaluation 81183 Yes Yes to detect abnormal (e.g., expanded) alleles CACNA1A (calcium voltage-gated channel subunit alpha1 A) (e.g., 81184 spinocerebellar ataxia) gene analysis; evaluation to detect abnormal (e.g., Yes Yes expanded) alleles CACNA1A (calcium voltage-gated channel subunit alpha1 A) (e.g., 81185 Yes Yes spinocerebellar ataxia) gene analysis; full gene sequence CNBP (CCHC-type zinc finger nucleic acid binding protein) (e.g., myotonic 81187 dystrophy type 2) gene analysis, evaluation to detect abnormal (e.g., Yes Yes expanded) alleles CSTB (cystatin B) (e.g., Unverricht-Lundborg disease) gene analysis; 81188 Yes Yes evaluation to detect abnormal (e.g., expanded) alleles Confidential and Proprietary Information of Avalon Health Services, LLC, d/b/a Avalon Healthcare Solutions PA-TOOL-6032-V02-20170124-Prior Authorization List 2 Procedure PA for PA for Description Code 7/1/2020 9/1/2020 CSTB (cystatin B) (e.g., Unverricht-Lundborg disease) gene analysis; full 81189 Yes Yes gene sequence ASPA (aspartoacylase) (e.g., Canavan disease) gene analysis, common 81200 variants (e.g., E285A, Y231X) (ASPA genetic analysis, CANW, or Canavan Yes Yes disease mutation analysis) APC (adenomatous polyposis coli) (e.g., familial adenomatous polyposis 81201 Yes Yes [FAP], attenuated FAP) gene analysis; full gene sequence APC (adenomatous polyposis coli) (e.g., familial adenomatous polyposis 81202 Yes Yes [FAP], attenuated FAP) gene analysis; known familial variants APC (adenomatous polyposis coli) (e.g., familial adenomatous polyposis 81203 Yes Yes [FAP], attenuated FAP) gene analysis; duplication/deletion variants AR (androgen receptor) (e.g., spinal and bulbar muscular atrophy, Kennedy 81204 disease, X chromosome inactivation) gene analysis; characterization of Yes Yes alleles (e.g., expanded size or methylation status) BCKDHB (branched-chain keto acid dehydrogenase E1, beta polypeptide) 81205 (e.g., Maple syrup urine disease) gene analysis, common variants (e.g., Yes Yes R183P, G278S, E422X) BCR/ABL1 (t(9:22)) (e.g., chronic myelogenous leukemia) translocation 81206 Yes Yes analysis; major breakpoint, qualitative or quantitative BCR/ABL1 (t(9;22)) (e.g., chronic myelogenous leukemia) translocation 81207 Yes Yes analysis; minor breakpoint qualitative or quantitative BCR/ABL1 (t(9;22)) (e.g., chronic myelogenous leukemia) translocation 81208 Yes Yes analysis; other breakpoint, qualitative or quantitative BLM (Bloom Syndrome, RecQ helicase-like) (e.g., Bloom Syndrome) gene 81209 Yes Yes analysis, 2281del6ins7 variant BRAF (B-Raf proto-oncogene, serine/threonine kinase) (e.g., colon cancer, 81210 Yes Yes melanoma), gene analysis, V600 variants BRCA1 (BRCA1, DNA repair associated), BRCA2 (BRCA2, DNA repair 81212 associated) (e.g., hereditary breast and ovarian cancer) gene analysis; Yes Yes 185delAG, 5385insC, 6174delT variants BRCA1 (BRCA1, DNA repair associated) (e.g., hereditary breast and ovarian 81215 Yes Yes cancer) gene analysis; known familial variant BRCA2 (BRCA2, DNA repair associated) (e.g., hereditary breast and ovarian 81216 Yes Yes cancer) gene analysis; full sequence analysis BRCA2 (BRCA2, DNA repair associated) (e.g., hereditary breast and ovarian 81217 Yes Yes cancer) gene analysis; known familial variant CEBPA (CCAAT/enhancer binding protein [C/EBP], alpha) (e.g., acute 81218 Yes Yes myeloid leukemia), gene analysis, full gene sequence CALR (calreticulin) (e.g., myeloproliferative disorders), gene analysis, 81219 Yes Yes common variants in exon 9 CFTR (cystic fibrosis transmembrane conductance regulator) (e.g., cystic 81221 Yes Yes fibrosis) gene analysis; known familial variants CFTR (cystic fibrosis transmembrane conductance regulator) (e.g., cystic 81222 Yes Yes fibrosis) gene analysis; duplication/deletion variants CFTR (cystic fibrosis transmembrane conductance regulator) (e.g., cystic 81223 Yes Yes fibrosis) gene analysis; full gene sequence Confidential and Proprietary Information of Avalon Health Services, LLC, d/b/a Avalon Healthcare Solutions PA-TOOL-6032-V02-20170124-Prior
Load more

Recommended publications
  • Imm Catalog.Pdf
    $ Gene Symbol A B 3 C 4 D 9 E 10 F 11 G 12 H 13 I 14 J. K 17 L 18 M 19 N 20 O. P 22 R 26 S 27 T 30 U 32 V. W. X. Y. Z 33 A ® ® Gene Symbol Gene ID Antibody Monoclonal Antibody Polyclonal MaxPab Full-length Protein Partial-length Protein Antibody Pair KIt siRNA/Chimera Gene Symbol Gene ID Antibody Monoclonal Antibody Polyclonal MaxPab Full-length Protein Partial-length Protein Antibody Pair KIt siRNA/Chimera A1CF 29974 ● ● ADAMTS13 11093 ● ● ● ● ● A2M 2 ● ● ● ● ● ● ADAMTS20 80070 ● AACS 65985 ● ● ● ADAMTS5 11096 ● ● ● AANAT 15 ● ● ADAMTS8 11095 ● ● ● ● AATF 26574 ● ● ● ● ● ADAMTSL2 9719 ● AATK 9625 ● ● ● ● ADAMTSL4 54507 ● ● ABCA1 19 ● ● ● ● ● ADAR 103 ● ● ABCA5 23461 ● ● ADARB1 104 ● ● ● ● ABCA7 10347 ● ADARB2 105 ● ABCB9 23457 ● ● ● ● ● ADAT1 23536 ● ● ABCC4 10257 ● ● ● ● ADAT2 134637 ● ● ABCC5 10057 ● ● ● ● ● ADAT3 113179 ● ● ● ABCC8 6833 ● ● ● ● ADCY10 55811 ● ● ABCD2 225 ● ADD1 118 ● ● ● ● ● ● ABCD4 5826 ● ● ● ADD3 120 ● ● ● ABCG1 9619 ● ● ● ● ● ADH5 128 ● ● ● ● ● ● ABL1 25 ● ● ADIPOQ 9370 ● ● ● ● ● ABL2 27 ● ● ● ● ● ADK 132 ● ● ● ● ● ABO 28 ● ● ADM 133 ● ● ● ABP1 26 ● ● ● ● ● ADNP 23394 ● ● ● ● ABR 29 ● ● ● ● ● ADORA1 134 ● ● ACAA2 10449 ● ● ● ● ADORA2A 135 ● ● ● ● ● ● ● ACAN 176 ● ● ● ● ● ● ADORA2B 136 ● ● ACE 1636 ● ● ● ● ADRA1A 148 ● ● ● ● ACE2 59272 ● ● ADRA1B 147 ● ● ACER2 340485 ● ADRA2A 150 ● ● ACHE 43 ● ● ● ● ● ● ADRB1 153 ● ● ACIN1 22985 ● ● ● ADRB2 154 ● ● ● ● ● ACOX1 51 ● ● ● ● ● ADRB3 155 ● ● ● ● ACP5 54 ● ● ● ● ● ● ● ADRBK1 156 ● ● ● ● ACSF2 80221 ● ● ADRM1 11047 ● ● ● ● ACSF3 197322 ● ● AEBP1 165 ● ● ● ● ACSL4 2182 ●
    [Show full text]
  • Cleveland Clinic Laboratories
    Cleveland Clinic Laboratories Technical Update • May 2014 Cleveland Clinic Laboratories is dedicated to keeping you updated and informed about recent testing changes. That's why we are happy to provide this technical update on a monthly basis. Recently changed tests are bolded, and could include revisions to methodology, reference range, days performed or CPT code. For your convenience, tests are listed alphabetically and the order and billing codes are provided. If you wish to compare the new information with previous test demographics, refer to the Test Directory, which can be accessed at clevelandcliniclabs.com. Deleted tests and new tests are listed separately. Please update your database as necessary. For additional detail, contact Client Services at 216.444.5755 or 800.628.6816 or via email at [email protected]. Days Performed/Reported Specimen Requirement Special InformationComponent Change Test Discontinued Reference Range Test Update Name Change Methodology Order CodeBiling Code New Test Page # Summary of Changes CPT by Test Name 3 5-Hydroxyindolacetic Acid, Urine 3 11-Deoxycorticosterone Qt, Serum / Plasma 3 25-Hydroxyvitamin D2 and D3, Serum 9 Alpha-1 Antitrypsin (SERPINA1) Targeted Genotyping 3 Alpha-1-Antitrypsin Clearance 3 Alpha-1-Antitrypsin, Stool 3 Anti IgA Antibody 3 Anti Mullerian Hormone 3 Beta Galactosidase, Leukocytes 4 Bioavailable Testosterone / SHBG, Female & Child 4 BK Virus Quantitation, Urine 12 Buprenorphine & Metabolite, Confirmation / Quant, Urine 9 Buprenorphine Quant, Urine 4 Carnitine Free & Total,
    [Show full text]
  • Genes in Eyecare Geneseyedoc 3 W.M
    Genes in Eyecare geneseyedoc 3 W.M. Lyle and T.D. Williams 15 Mar 04 This information has been gathered from several sources; however, the principal source is V. A. McKusick’s Mendelian Inheritance in Man on CD-ROM. Baltimore, Johns Hopkins University Press, 1998. Other sources include McKusick’s, Mendelian Inheritance in Man. Catalogs of Human Genes and Genetic Disorders. Baltimore. Johns Hopkins University Press 1998 (12th edition). http://www.ncbi.nlm.nih.gov/Omim See also S.P.Daiger, L.S. Sullivan, and B.J.F. Rossiter Ret Net http://www.sph.uth.tmc.edu/Retnet disease.htm/. Also E.I. Traboulsi’s, Genetic Diseases of the Eye, New York, Oxford University Press, 1998. And Genetics in Primary Eyecare and Clinical Medicine by M.R. Seashore and R.S.Wappner, Appleton and Lange 1996. M. Ridley’s book Genome published in 2000 by Perennial provides additional information. Ridley estimates that we have 60,000 to 80,000 genes. See also R.M. Henig’s book The Monk in the Garden: The Lost and Found Genius of Gregor Mendel, published by Houghton Mifflin in 2001 which tells about the Father of Genetics. The 3rd edition of F. H. Roy’s book Ocular Syndromes and Systemic Diseases published by Lippincott Williams & Wilkins in 2002 facilitates differential diagnosis. Additional information is provided in D. Pavan-Langston’s Manual of Ocular Diagnosis and Therapy (5th edition) published by Lippincott Williams & Wilkins in 2002. M.A. Foote wrote Basic Human Genetics for Medical Writers in the AMWA Journal 2002;17:7-17. A compilation such as this might suggest that one gene = one disease.
    [Show full text]
  • Supplementary Table S2
    1-high in cerebrotropic Gene P-value patients Definition BCHE 2.00E-04 1 Butyrylcholinesterase PLCB2 2.00E-04 -1 Phospholipase C, beta 2 SF3B1 2.00E-04 -1 Splicing factor 3b, subunit 1 BCHE 0.00022 1 Butyrylcholinesterase ZNF721 0.00028 -1 Zinc finger protein 721 GNAI1 0.00044 1 Guanine nucleotide binding protein (G protein), alpha inhibiting activity polypeptide 1 GNAI1 0.00049 1 Guanine nucleotide binding protein (G protein), alpha inhibiting activity polypeptide 1 PDE1B 0.00069 -1 Phosphodiesterase 1B, calmodulin-dependent MCOLN2 0.00085 -1 Mucolipin 2 PGCP 0.00116 1 Plasma glutamate carboxypeptidase TMX4 0.00116 1 Thioredoxin-related transmembrane protein 4 C10orf11 0.00142 1 Chromosome 10 open reading frame 11 TRIM14 0.00156 -1 Tripartite motif-containing 14 APOBEC3D 0.00173 -1 Apolipoprotein B mRNA editing enzyme, catalytic polypeptide-like 3D ANXA6 0.00185 -1 Annexin A6 NOS3 0.00209 -1 Nitric oxide synthase 3 SELI 0.00209 -1 Selenoprotein I NYNRIN 0.0023 -1 NYN domain and retroviral integrase containing ANKFY1 0.00253 -1 Ankyrin repeat and FYVE domain containing 1 APOBEC3F 0.00278 -1 Apolipoprotein B mRNA editing enzyme, catalytic polypeptide-like 3F EBI2 0.00278 -1 Epstein-Barr virus induced gene 2 ETHE1 0.00278 1 Ethylmalonic encephalopathy 1 PDE7A 0.00278 -1 Phosphodiesterase 7A HLA-DOA 0.00305 -1 Major histocompatibility complex, class II, DO alpha SOX13 0.00305 1 SRY (sex determining region Y)-box 13 ABHD2 3.34E-03 1 Abhydrolase domain containing 2 MOCS2 0.00334 1 Molybdenum cofactor synthesis 2 TTLL6 0.00365 -1 Tubulin tyrosine ligase-like family, member 6 SHANK3 0.00394 -1 SH3 and multiple ankyrin repeat domains 3 ADCY4 0.004 -1 Adenylate cyclase 4 CD3D 0.004 -1 CD3d molecule, delta (CD3-TCR complex) (CD3D), transcript variant 1, mRNA.
    [Show full text]
  • Introduction to the Rh Blood Group.Pdf
    Introduction to the Rhesus Blood Group Justin R. Rhees, M.S., MLS(ASCP)CM, SBBCM University of Utah Department of Pathology Medical Laboratory Science Program Objectives 1. Describe the major Rhesus (Rh) blood group antigens in terms of biochemical structure and inheritance. 2. Describe the characteristics of Rh antibodies. 3. Translate the five major Rh antigens, genotypes, and haplotypes from Fisher-Race to Wiener nomenclature. 4. State the purpose of Fisher-Race, Wiener, Rosenfield, and ISBT nomenclatures. Background . How did this blood group get its name? . 1937 Mrs. Seno; Bellevue hospital . Unknown antibody, unrelated to ABO . Philip Levine tested her serum against 54 ABO-compatible blood samples: only 13 were compatible. Rhesus (Rh) blood group 1930s several cases of Hemolytic of the Fetus and Newborn (HDFN) published. Hemolytic transfusion reactions (HTR) were observed in ABO- compatible transfusions. In search of more blood groups, Landsteiner and Wiener immunized rabbits with the Rhesus macaque blood of the Rhesus monkeys. Rhesus (Rh) blood group 1940 Landsteiner and Wiener reported an antibody that reacted with about 85% of human red cell samples. It was supposed that anti-Rh was the specificity causing the “intragroup” incompatibilities observed. 1941 Levine found in over 90% of erythroblastosis fetalis cases, the mother was Rh-negative and the father was Rh-positive. Rhesus macaque Rhesus (Rh) blood group Human anti-Rh and animal anti- Rh are not the same. However, “Rh” was embedded into blood group antigen terminology. The
    [Show full text]
  • Genetic Testing Policy Number: PG0041 ADVANTAGE | ELITE | HMO Last Review: 04/11/2021
    Genetic Testing Policy Number: PG0041 ADVANTAGE | ELITE | HMO Last Review: 04/11/2021 INDIVIDUAL MARKETPLACE | PROMEDICA MEDICARE PLAN | PPO GUIDELINES This policy does not certify benefits or authorization of benefits, which is designated by each individual policyholder terms, conditions, exclusions and limitations contract. It does not constitute a contract or guarantee regarding coverage or reimbursement/payment. Paramount applies coding edits to all medical claims through coding logic software to evaluate the accuracy and adherence to accepted national standards. This medical policy is solely for guiding medical necessity and explaining correct procedure reporting used to assist in making coverage decisions and administering benefits. SCOPE X Professional X Facility DESCRIPTION A genetic test is the analysis of human DNA, RNA, chromosomes, proteins, or certain metabolites in order to detect alterations related to a heritable or acquired disorder. This can be accomplished by directly examining the DNA or RNA that makes up a gene (direct testing), looking at markers co-inherited with a disease-causing gene (linkage testing), assaying certain metabolites (biochemical testing), or examining the chromosomes (cytogenetic testing). Clinical genetic tests are those in which specimens are examined and results reported to the provider or patient for the purpose of diagnosis, prevention or treatment in the care of individual patients. Genetic testing is performed for a variety of intended uses: Diagnostic testing (to diagnose disease) Predictive
    [Show full text]
  • Engineered Type 1 Regulatory T Cells Designed for Clinical Use Kill Primary
    ARTICLE Acute Myeloid Leukemia Engineered type 1 regulatory T cells designed Ferrata Storti Foundation for clinical use kill primary pediatric acute myeloid leukemia cells Brandon Cieniewicz,1* Molly Javier Uyeda,1,2* Ping (Pauline) Chen,1 Ece Canan Sayitoglu,1 Jeffrey Mao-Hwa Liu,1 Grazia Andolfi,3 Katharine Greenthal,1 Alice Bertaina,1,4 Silvia Gregori,3 Rosa Bacchetta,1,4 Norman James Lacayo,1 Alma-Martina Cepika1,4# and Maria Grazia Roncarolo1,2,4# Haematologica 2021 Volume 106(10):2588-2597 1Department of Pediatrics, Division of Stem Cell Transplantation and Regenerative Medicine, Stanford School of Medicine, Stanford, CA, USA; 2Stanford Institute for Stem Cell Biology and Regenerative Medicine, Stanford School of Medicine, Stanford, CA, USA; 3San Raffaele Telethon Institute for Gene Therapy, Milan, Italy and 4Center for Definitive and Curative Medicine, Stanford School of Medicine, Stanford, CA, USA *BC and MJU contributed equally as co-first authors #AMC and MGR contributed equally as co-senior authors ABSTRACT ype 1 regulatory (Tr1) T cells induced by enforced expression of interleukin-10 (LV-10) are being developed as a novel treatment for Tchemotherapy-resistant myeloid leukemias. In vivo, LV-10 cells do not cause graft-versus-host disease while mediating graft-versus-leukemia effect against adult acute myeloid leukemia (AML). Since pediatric AML (pAML) and adult AML are different on a genetic and epigenetic level, we investigate herein whether LV-10 cells also efficiently kill pAML cells. We show that the majority of primary pAML are killed by LV-10 cells, with different levels of sensitivity to killing. Transcriptionally, pAML sensitive to LV-10 killing expressed a myeloid maturation signature.
    [Show full text]
  • Gene Expression Predictors of Breast Cancer Outcomes
    GENE EXPRESSION PREDICTORS OF BREAST CANCER OUTCOMES Erich Huang2, Skye H Cheng1, Holly Dressman2, Jennifer Pittman5, Mei-Hua Tsou1, Cheng-Fang Horng1, Andrea Bild2, Edwin S Iversen4,5, Ming Liao5, Chii-Ming Chen1, Mike West5, Joseph R Nevins2,6 and Andrew T Huang1,3 1Koo Foundation Sun Yat-Sen Cancer Center, Taipei, Taiwan 2Department of Molecular Genetics and Microbiology, Duke University Medical Center 3Department of Medicine, Duke University Medical Center 4Department of Biostatistics and Bioinformatics, Duke University Medical Center 5Institute of Statistics and Decision Sciences, Duke University 6Howard Hughes Medical Institute SUMMARY Background The integration of currently accepted risk factors with genomic data carries the promise of focusing the practice of medicine on the individual patient. Such integration requires interpreting the complex, multivariate patterns in gene expression data, and evaluating their capacity to improve clinical predictions. We do this here, in a study of predicting nodal metastatic states and relapse for breast cancer patients. Methods DNA microarray data from samples of primary breast tumors were analyzed using non-linear statistical analyses to evaluate multiple patterns of interactions of groups of genes that have predictive value, at the individual patient level, with respect to lymph node metastasis and cancer recurrence. Findings We identify aggregate patterns of gene expression (metagenes) that associate with lymph node status and recurrence, and that are capable of honestly predicting outcomes in individual patients with about 90% accuracy. The identified metagenes define distinct groups of genes, suggesting different biological processes underlying these two characteristics of breast cancer. Initial external validation comes from similarly accurate predictions of nodal status of a small sample in a quite distinct population group.
    [Show full text]
  • Red Cell Transfusion and Alloimmunization in Sickle Cell Disease Ferrata Storti Foundation
    REVIEW ARTICLE Red cell transfusion and alloimmunization in sickle cell disease Ferrata Storti Foundation Grace E. Linder 1 and Stella T. Chou 2 1Department of Pathology and Lab Medicine, Children’s Hospital of Philadelphia, and 2Department of Pediatrics, Children’s Hospital of Philadelphia, Philadelphia, PA, USA ABSTRACT Haematologica 2021 ed cell transfusion remains a critical component of care for acute Volume 106(7):1805-1815 and chronic complications of sickle cell disease. Randomized clin - Rical trials demonstrated the benefits of transfusion therapy for prevention of primary and secondary strokes and postoperative acute chest syndrome. Transfusion for splenic sequestration, acute chest syn - drome, and acute stroke are guided by expert consensus recommenda - tions. Despite overall improvements in blood inventory safety, adverse effects of transfusion are prevalent among patients with sickle cell dis - ease and include alloimmunization, acute and delayed hemolytic trans - fusion reactions, and iron overload. Judicious use of red cell transfu - sions, optimization of red cell antigen matching, and the use of erythro - cytapheresis and iron chelation can minimize adverse effects. Early recognition and management of hemolytic transfusion reactions can avert poor clinical outcomes. In this review, we discuss transfusion methods, indications, and complications in sickle cell disease with an emphasis on alloimmunization. Introduction Transfusion remains a central intervention for sickle cell disease (SCD), with most patients receiving one or more transfusions by adulthood. 1 Prospective, ran - domized clinical trials support transfusion for primary and secondary stroke pre - vention, but for many other indications, treatment is based on expert consensus. Correspondence: Guidelines on transfusion management for SCD are limited by availability of well- designed studies.
    [Show full text]
  • Supplementary Materials: Molecular Signature of Subtypes of Non- Small Cell Lung Cancer by Large-Scale Transcriptional Profiling
    Cancers 2020 S1 of S18 Supplementary Materials: Molecular Signature of Subtypes of Non- Small Cell Lung Cancer by Large-Scale Transcriptional Profiling: Identification of Key Modules and Genes by Weighted Gene Co- Expression Network Analysis (WGCNA) Magdalena Niemira, Francois Collin, Anna Szalkowska, Agnieszka Bielska, Karolina Chwialkowska, Joanna Reszec, Jacek Niklinski, Miroslaw Kwasniewski and Adam Kretowski Cancers 2020 S2 of S18 A B Figure S1. The top-ranked enriched canonical pathway identified in (A) SCC and (B) ADC using IPA: Eicosanoid signalling pathway. Cancers 2020 S3 of S18 A Cancers 2020 S4 of S18 Figure S2. The second-ranked enriched canonical pathway identified in (A) SCC and (B) ADC using IPA: Agranulocyte adhesion and diapedesis. Cancers 2020 S5 of S18 Figure S3. The top-ranked enriched canonical pathway identified only in lung ADC: MIF regulation of innate immunity. A B Figure S4. Cluster dendograms of the gene clusters of (A) LUAD and (B) LUSC subset from TCGA database. Cancers 2020 S6 of S18 A B C D Figure S5. Protein-protein interaction (PPI) network of genes in the red (A), lightcyan (B), darkorange (C), yellow (D) modules in ADC. The networks were constructed using Cytoscape v. 3.7.2. software. Cancers 2020 S7 of S18 A B Figure S6. Protein-protein interaction (PPI) network of genes in the blue (A) and (B) modules in SCC. The networks were constructed using Cytoscape v. 3.7.2. software. Cancers 2020 S8 of S18 Table S1. Upstream regulator analysis of DEGs in lung SCC predicted by IPA. Upstream Prediction Target
    [Show full text]
  • CD System of Surface Molecules
    THE CD SYSTEM OF LEUKOCYTE APPENDIX 4A SURFACE MOLECULES Monoclonal Antibodies to Human Cell Surface Antigens APPENDIX 4A Alice Beare,1 Hannes Stockinger,2 Heddy Zola,1 and Ian Nicholson1 1Women’s and Children’s Health Research Institute, Women’s and Children’s Hospital, Adelaide, Australia 2Institute of Immunology, University of Vienna, Vienna ABSTRACT Many of the leukocyte cell surface molecules are known by “CD” numbers. In this Appendix, a short introduction describes the history and the use of CD nomenclature and provides a few key references to enable access to the wider literature. This is followed by a table that lists all human molecules with approved CD names, tabulating alternative names, key structural features, cellular expression, major known functions, and usefulness of the molecules or antibodies against them in research or clinical applications. Curr. Protoc. Immunol. 80:A.4A.1-A.4A.73. C 2008 by John Wiley & Sons, Inc. Keywords: CD nomenclature r HLDA r HCDM r leukocyte marker r human leukocyte differentiation r antigens INTRODUCTION During the last 25 years, large numbers of monoclonal antibodies (MAbs) have been pro- duced that have facilitated the purification and functional characterization of a plethora of leukocyte surface molecules. The antibodies have been even more useful as markers for cell populations, allowing the counting, separation, and functional study of numer- ous subsets of cells of the immune system. A series of international workshops were instrumental in coordinating this development through multi-laboratory “blind” studies of thousands of antibodies. These HLDA (Human Leukocyte Differentiation Antigens) Workshops have, up until now, defined 500 different entities and assigned them cluster of differentiation (CD) designations.
    [Show full text]
  • RHCE Variant Allele: RHCE*Ce254g,733G
    B LOOD G ROUP A LL E L E R E PORT RHCE variant allele: RHCE*ce254G,733G J.A. Keller, T. Horn, C. Chiappa, C. Melland, C. Vietz, L. Castilho, and M.A. Keller A novel RHCE allele was identified in a 53-year-old African- the consensus sequence using Sequencher 5.0 (GeneCodes American female blood donor with an Rh phenotype of D+ C– Corporation, Ann Arbor, MI). E– c+ e+ and a negative antibody screen. The donor’s cells typed e+ with all antisera tested. By gel-based genotyping and cDNA analysis, the two RHCE alleles in this donor were characterized. Results One allele was found to be the known allele RHCE*01.20.01 (RHCE*ce733G) and the second was novel: RHCE*01.06.02 A variety of gel-based genotyping assays were used (RHCE*ce254G,733G). Immunohematology 2014;30:121– 122. to screen the donor sample for known single nucleotide polymorphisms (SNPs). The results are summarized in Table 1. cDNA analysis was performed to further characterize Case Report the two RHCE alleles to rule out the presence of additional variants. One allele was found to be known: RHCE*01.20.01 A novel RHCE allele, RHCE*ce254G,733G, was identified (RHCE*ce733G). The second allele has not been reported in a 53-year-old African-American female blood donor with previously; it carries two SNPs: RHCE c.254G and c.733G. an Rh phenotype of D+ C– E– c+ e+ and a negative antibody The allele was named RHCE*ce254G,733G (Table 2) based on screen.
    [Show full text]